Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years

被引：0
|
作者：
Auer, M. [1 ]
Zinganell, A. [1 ]
Hegen, H. [1 ]
Bsteh, G. [2 ]
Di Pauli, F. [1 ]
Berek, K. [1 ]
Fava, E. [1 ]
Wurth, S. [3 ]
Berger, T. [2 ]
Deisenhammer, F. [1 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Med Univ Graz, Graz, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P693
引用
收藏
页码：588 / 588
页数：1
相关论文
共 50 条
  • [31] Real-life experience with sNFL in multiple sclerosis patients, as monitoring and treatment decision biomarker
    Valentino, P.
    Marnetto, F.
    Bava, C.
    Martire, S.
    Bertolotto, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 85 - 86
  • [32] Real-life experiences with omalizumab for the treatment of chronic urticaria
    Sussman, Gordon
    Hebert, Jacques
    Barron, Carly
    Bian, Jia
    Caron-Guay, Rose-Marie
    Laflamme, Stephanie
    Stern, Simon
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 112 (02) : 170 - 174
  • [33] Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort
    Manni, Alessia
    Direnzo, Vita
    Iaffaldano, Antonio
    Di Lecce, Valentina
    Tortorella, Carla
    Zoccolella, Stefano
    Iaffaldano, Pietro
    Trojano, Maria
    Paolicelli, Damiano
    BRAIN AND BEHAVIOR, 2017, 7 (10):
  • [34] Cyclophosphamide in multiple sclerosis: a real-life study on 222 patients
    Beaufils, P. Constant Dit
    Laplaud, D. A.
    Jousset, N.
    Lefrere, F.
    Wiertlewski, S.
    Michel, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 897 - 897
  • [35] Natalizumab: real life adherence to disease modifying therapy in multiple sclerosis care
    Gudesblatt, M.
    Gorbatsevych, O.
    Bumstead, B.
    Zarif, M.
    Thippeswamy, G.
    Thotam, S.
    Fafard, L.
    Buhse, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 482 - 482
  • [36] Safety assessment of a natalizumab home administration procedure: results from a real-life cohort at the Lille university hospital
    Lafontaine, J. -C.
    Boucher, J.
    Giovannelli, J.
    Outteryck, O.
    Balagny, S.
    Zephir, H.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 867 - 867
  • [37] Reperfusion Treatment for STEMI in Age Over 75 Years: Unsatisfactory Real-Life Practice
    Monhart, Zdenek
    Grunfeldova, Hana
    Zvarova, Jana
    Jansky, Petr
    CIRCULATION, 2010, 122 (02) : E69 - E69
  • [38] Changes in the quality of life of multiple sclerosis patients treated with natalizumab after one or two years' treatment: Hungarian natalizumab database results
    Bencsik, K.
    Karacsony, M.
    Rozsa, Cs
    Lovas, G.
    Kovacs, K.
    Cseh, B.
    Pentek, Sz
    Ruhm, G.
    Imre, P.
    Kovacs, Z. M.
    Simo, M.
    Dobos, E.
    Jakab, G.
    Komoly, S.
    Vecsei, L.
    Csepany, T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 286 - 287
  • [39] Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 198 - 198
  • [40] Dimethyl-fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study
    Conde, S.
    Moisset, X.
    Pereira, B.
    Zuel, M.
    Colamarino, R.
    Maillet-Vioud, M.
    Lauxerois, M.
    Taithe, F.
    Clavelou, P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 688 - 689
12345